Anthony T. Reder to Humans
This is a "connection" page, showing publications Anthony T. Reder has written about Humans.
Connection Strength
0.953
-
Novel biomarkers and interferon signature in secondary progressive multiple sclerosis. J Neuroimmunol. 2024 Apr 15; 389:578328.
Score: 0.032
-
Clostridium epsilon toxin is excessive in multiple sclerosis and provokes multifocal lesions in mouse models. J Clin Invest. 2023 05 01; 133(9).
Score: 0.030
-
Prolonged Interferon-Stimulated Gene and Protein Signatures in Multiple Sclerosis Induced by PEGylated IFN-ß-1a Compared to Non-PEGylated IFN-ß-1a. J Interferon Cytokine Res. 2023 03; 43(3):108-120.
Score: 0.030
-
T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy. Mult Scler. 2023 05; 29(6):648-656.
Score: 0.029
-
Medications for Multiple Sclerosis and Risk of Malignancy: What Next? Neurotherapeutics. 2021 07; 18(3):1650-1653.
Score: 0.027
-
Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021 Jun; 51:102935.
Score: 0.026
-
Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis. Mult Scler. 2021 12; 27(14):2170-2179.
Score: 0.026
-
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
Score: 0.026
-
Asymptomatic brainstem lesions and pachymeningeal enhancement after anti-PD-1 therapy. Immunotherapy. 2021 01; 13(1):11-17.
Score: 0.025
-
The rhythms of AMBEs (arousal-related motor behavioral episodes) in Agrypnia Excitata: a video motor analysis. Sleep Med. 2020 10; 74:224-226.
Score: 0.025
-
Thoracic flexion provokes circumferential dysesthesia: A symptom of thoracic cord lesions in MS. Mult Scler. 2021 06; 27(7):1008-1013.
Score: 0.025
-
Interferon-ß corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection. EBioMedicine. 2019 Nov; 49:269-283.
Score: 0.024
-
Vitamin D enhances responses to interferon-ß in MS. Neurol Neuroimmunol Neuroinflamm. 2019 11; 6(6):e622.
Score: 0.024
-
Dimethyl fumarate-induced changes in the MS lymphocyte repertoire: No need for subset monitoring. Neurology. 2019 04 09; 92(15):696-697.
Score: 0.023
-
Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment. Patient. 2016 Apr; 9(2):171-80.
Score: 0.019
-
The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis. CNS Drugs. 2016 Feb; 30(2):135-47.
Score: 0.018
-
How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms. J Interferon Cytokine Res. 2014 Aug; 34(8):589-99.
Score: 0.017
-
The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Mult Scler. 2013 Nov; 19(13):1765-72.
Score: 0.015
-
Response to GS Gronseth and E Ashman. Mult Scler. 2012 Nov; 18(11):1661-2; author reply 1663-4.
Score: 0.015
-
Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins. Arch Neurol. 2012 Oct; 69(10):1303-9.
Score: 0.015
-
Evidence-based medicine: promise and pitfalls. Mult Scler. 2012 Jul; 18(7):947-8.
Score: 0.014
-
MxA: a biomarker for predicting multiple sclerosis disease activity. Neurology. 2010 Oct 05; 75(14):1222-3.
Score: 0.013
-
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology. 2010 Jun 08; 74(23):1877-85.
Score: 0.012
-
Multiple sclerosis. Part I: neuro-ophthalmic manifestations. Curr Opin Ophthalmol. 2009 Nov; 20(6):467-75.
Score: 0.012
-
4-Aminopyridine toxicity mimics autoimmune-mediated limbic encephalitis. Neurology. 2009 Mar 24; 72(12):1100-1.
Score: 0.011
-
Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler. 2008 Jul; 14(6):809-14.
Score: 0.011
-
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008 Oct 28; 71(18):1390-5.
Score: 0.011
-
IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J Interferon Cytokine Res. 2008 May; 28(5):317-31.
Score: 0.011
-
Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Mult Scler. 2007 May; 13(4):459-70.
Score: 0.010
-
Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol Ther. 2006 Apr; 110(1):35-56.
Score: 0.009
-
Anti-myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis. Neurology. 2004 Jun 08; 62(11):1922-3.
Score: 0.008
-
Adeno-associated viral vector-mediated ApoE expression in Alzheimer's disease mice: low CNS immune response, long-term expression, and astrocyte specificity. Front Biosci. 2004 May 01; 9:1540-6.
Score: 0.008
-
Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis. Front Biosci. 2004 May 01; 9:1547-55.
Score: 0.008
-
Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial. Mult Scler Relat Disord. 2023 Aug; 76:104794.
Score: 0.008
-
Understanding humoral immunity and multiple sclerosis severity in Black, and Latinx patients. Front Immunol. 2023; 14:1172993.
Score: 0.008
-
Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study. Mult Scler Relat Disord. 2023 Jun; 74:104718.
Score: 0.008
-
Psychometric evaluation of the Chicago Multiscale Depression Inventory in multiple sclerosis patients. Mult Scler. 2003 Mar; 9(2):160-70.
Score: 0.007
-
Effectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: A single-center retrospective study. Mult Scler Relat Disord. 2023 Mar; 71:104523.
Score: 0.007
-
Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol. 2002 Aug; 129(1-2):205-15.
Score: 0.007
-
Proposal of new diagnostic criteria for fatal familial insomnia. J Neurol. 2022 Sep; 269(9):4909-4919.
Score: 0.007
-
Type I interferons inhibit interleukin-10 production in activated human monocytes and stimulate IL-10 in T cells: implications for Th1-mediated diseases. J Interferon Cytokine Res. 2002 Mar; 22(3):311-9.
Score: 0.007
-
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Mult Scler. 2022 04; 28(5):790-800.
Score: 0.007
-
Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). CNS Drugs. 2021 07; 35(7):743-767.
Score: 0.007
-
Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis. Mult Scler. 2021 12; 27(14):2219-2231.
Score: 0.007
-
Injecting rationale into interferon-beta therapy. Neurology. 2000 Jun 13; 54(11):2034-5.
Score: 0.006
-
Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. PLoS One. 2018; 13(12):e0209326.
Score: 0.006
-
Monocyte activation in multiple sclerosis. Mult Scler. 1998 Jun; 4(3):162-8.
Score: 0.005
-
Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b. Mult Scler. 2019 05; 25(6):837-847.
Score: 0.005
-
Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. Epilepsy Behav. 2018 03; 80:331-336.
Score: 0.005
-
Effects of an anti-IL-10 monoclonal antibody on rIFNbeta-1b-mediated immune modulation. Relevance to multiple sclerosis. J Neuroimmunol. 1998 Jan; 81(1-2):109-15.
Score: 0.005
-
Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon ß-1a in the EVIDENCE study. J Neurol Sci. 2017 Aug 15; 379:151-156.
Score: 0.005
-
Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature. Mult Scler Relat Disord. 2016 Sep; 9:158-62.
Score: 0.005
-
Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult Scler. 1996 Apr; 1(5):262-9.
Score: 0.005
-
Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Jan; 15(1):35-46.
Score: 0.005
-
Relapses in multiple sclerosis: Relationship to disability. Mult Scler Relat Disord. 2016 Mar; 6:10-20.
Score: 0.004
-
Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J Neuroimmunol. 1995 Aug; 61(1):27-34.
Score: 0.004
-
Clinical and genetic studies of fatal familial insomnia. Neurology. 1995 Jun; 45(6):1068-75.
Score: 0.004
-
Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology. 1995 Jun; 45(6):1097-100.
Score: 0.004
-
Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015 Jan; 72(1):31-9.
Score: 0.004
-
Induction of a unique isoform of the NCOA7 oxidation resistance gene by interferon ß-1b. J Interferon Cytokine Res. 2015 Mar; 35(3):186-99.
Score: 0.004
-
IFN-gamma, IFN-beta, and PGE1 affect monokine secretion: relevance to monocyte activation in multiple sclerosis. Cell Immunol. 1994 Sep; 157(2):428-38.
Score: 0.004
-
First-dose effects of fingolimod: Pooled safety data from three phase 3 studies. Mult Scler Relat Disord. 2014 Sep; 3(5):629-38.
Score: 0.004
-
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun; 13(6):545-56.
Score: 0.004
-
Adrenal size is increased in multiple sclerosis. Arch Neurol. 1994 Feb; 51(2):151-4.
Score: 0.004
-
Validity of the Neurology Quality-of-Life (Neuro-QoL) measurement system in adult epilepsy. Epilepsy Behav. 2014 Feb; 31:77-84.
Score: 0.004
-
Genetic variation near IRF8 is associated with serologic and cytokine profiles in systemic lupus erythematosus and multiple sclerosis. Genes Immun. 2013 Dec; 14(8):471-8.
Score: 0.004
-
Serum prolactin levels in active multiple sclerosis and during cyclosporin treatment. J Neurol Sci. 1993 Jul; 117(1-2):192-6.
Score: 0.004
-
Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013 Jul; 120(7):1432-9.
Score: 0.004
-
Cystoid macular edema associated with fingolimod use for multiple sclerosis. JAMA Ophthalmol. 2013 Jan; 131(1):103-7.
Score: 0.004
-
Cytokines in the vitreous of patients with proliferative diabetic retinopathy. Am J Ophthalmol. 1992 Dec 15; 114(6):731-6.
Score: 0.004
-
Regulation of production of adrenocorticotropin-like proteins in human mononuclear cells. Immunology. 1992 Nov; 77(3):436-42.
Score: 0.004
-
Treatment with interferon beta for multiple sclerosis. JAMA. 2012 Oct 24; 308(16):1627; author reply 1627-8.
Score: 0.004
-
Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. BMC Neurol. 2012 Jul 16; 12:55.
Score: 0.004
-
Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J. 2013 Oct; 13(5):443-51.
Score: 0.004
-
Interferon-beta treatment does not elevate cortisol in multiple sclerosis. J Interferon Res. 1992 Jun; 12(3):195-8.
Score: 0.004
-
Homonymous hemimacular thinning: a unique presentation of optic tract injury in neuromyelitis optica. J Neuroophthalmol. 2012 Jun; 32(2):150-3.
Score: 0.004
-
Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology. 2012 Jun 05; 78(23):1860-7.
Score: 0.004
-
Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNß-1b trial. Neurology. 2012 Apr 24; 78(17):1315-22.
Score: 0.004
-
Severe tetanus in immunized patients with high anti-tetanus titers. Neurology. 1992 Apr; 42(4):761-4.
Score: 0.004
-
Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler. 2012 Jun; 18(6):891-8.
Score: 0.003
-
Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon ß-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012 Mar; 83(3):282-7.
Score: 0.003
-
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011 Dec; 70(6):897-912.
Score: 0.003
-
Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One. 2011; 6(11):e22444.
Score: 0.003
-
Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J Neurol Sci. 2012 Feb 15; 313(1-2):48-53.
Score: 0.003
-
The function of the CD2 protein is abnormal in multiple sclerosis. J Autoimmun. 1991 Jun; 4(3):479-91.
Score: 0.003
-
Soluble CD8 levels in the CSF and serum of patients with multiple sclerosis. Neurology. 1991 Jun; 41(6):851-4.
Score: 0.003
-
Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol. 1991 Apr; 32(1):67-74.
Score: 0.003
-
Fingolimod for the treatment of relapsing multiple sclerosis. Expert Rev Neurother. 2011 Feb; 11(2):165-83.
Score: 0.003
-
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010 Jul; 9(7):740-50.
Score: 0.003
-
Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010 Aug; 81(8):907-12.
Score: 0.003
-
Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci. 2010 Mar 15; 290(1-2):16-21.
Score: 0.003
-
Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Mult Scler. 2010 Jan; 16(1):30-8.
Score: 0.003
-
Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. Curr Med Res Opin. 2009 Oct; 25(10):2459-70.
Score: 0.003
-
Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther. 2009 Aug; 31(8):1724-36.
Score: 0.003
-
Neuroendocrine regulation and the immune response in MS. Res Immunol. 1989 Feb; 140(2):239-45; discussion 245-8.
Score: 0.003
-
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology. 2008 Jul 08; 71(2):136-44.
Score: 0.003
-
Activated suppressor cell function in multiple sclerosis--clinical correlations. J Neuroimmunol. 1988 Mar; 17(4):323-30.
Score: 0.003
-
IFN-beta-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions. J Neuroimmunol. 2008 Mar; 195(1-2):116-20.
Score: 0.003
-
Blood lymphocyte beta-adrenergic receptors in multiple sclerosis. Ann N Y Acad Sci. 1988; 540:585-8.
Score: 0.003
-
ACTH production by human mononuclear cells. Ann N Y Acad Sci. 1988; 540:589-91.
Score: 0.003
-
Immunoregulation in rapidly progressive multiple sclerosis. Ann N Y Acad Sci. 1988; 540:4-12.
Score: 0.003
-
Dexamethasone suppression test abnormalities in multiple sclerosis: relation to ACTH therapy. Neurology. 1987 May; 37(5):849-53.
Score: 0.002
-
Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2007 Mar 27; 68(13):977-84.
Score: 0.002
-
Molecular analysis of the CD8 gene in multiple sclerosis. J Neuroimmunol. 1987 Mar; 14(2):183-7.
Score: 0.002
-
Neuroleukin: a lymphokine product of lectin-stimulated T cells. Science. 1986 Oct 31; 234(4776):574-81.
Score: 0.002
-
Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006 Feb 28; 66(4):472-6.
Score: 0.002
-
Low T8 antigen density on lymphocytes in active multiple sclerosis. Ann Neurol. 1984 Aug; 16(2):242-9.
Score: 0.002
-
Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler. 2004 Apr; 10(2):126-38.
Score: 0.002
-
T regulator cell surface antigens in multiple sclerosis. Ann N Y Acad Sci. 1984; 436:247-53.
Score: 0.002
-
Immunoregulation in multiple sclerosis. Ann N Y Acad Sci. 1984; 436:133-9.
Score: 0.002
-
Clinical spectrum of multiple sclerosis. Neurol Clin. 1983 Aug; 1(3):573-99.
Score: 0.002
-
B-cell differentiation in multiple sclerosis and the effect of intravenous ACTH. Neurology. 1983 Apr; 33(4):442-6.
Score: 0.002
-
Epilepsy evoked by eating: the role of peripheral input. Neurology. 1982 Sep; 32(9):1065-9.
Score: 0.002
-
Neurologic Munchausen's redux. Neurology. 1982 Feb; 32(2):216.
Score: 0.002
-
Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest. 1997 Jun 01; 99(11):2664-71.
Score: 0.001
-
Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology. 1996 Dec; 47(6):1463-8.
Score: 0.001
-
The mast cells of the multiple sclerosis brain. J Neuroimmunol. 1996 Nov; 70(2):131-8.
Score: 0.001
-
Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology. 1996 Jul; 47(1):129-39.
Score: 0.001
-
Mechanisms of action of interferon-beta in multiple sclerosis. Springer Semin Immunopathol. 1996; 18(1):125-48.
Score: 0.001
-
Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis. Ann Neurol. 1995 Oct; 38(4):625-32.
Score: 0.001
-
Increased high affinity beta-adrenergic receptor densities and cyclic AMP responses of CD8 cells in multiple sclerosis. J Neuroimmunol. 1993 Mar; 43(1-2):1-7.
Score: 0.001
-
T cell lymphokine-induced secretion of cytokines by monocytes from patients with multiple sclerosis. Cell Immunol. 1993 Jan; 146(1):96-106.
Score: 0.001
-
Increased muscarinic cholinergic receptor density on CD4+ lymphocytes in progressive multiple sclerosis. J Neuroimmunol. 1992 Feb; 36(2-3):171-7.
Score: 0.001
-
Three-dimensional human pattern visual evoked potentials. II. Multiple sclerosis patients. Electroencephalogr Clin Neurophysiol. 1991 Sep-Oct; 80(5):339-46.
Score: 0.001
-
Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28- suppressor cell. Ann Neurol. 1991 Jul; 30(1):42-7.
Score: 0.001
-
Internal capsule plaque and tonic spasms in multiple sclerosis. Arch Neurol. 1991 Apr; 48(4):427-9.
Score: 0.001
-
Sympathetic skin responses are decreased and lymphocyte beta-adrenergic receptors are increased in progressive multiple sclerosis. Ann Neurol. 1990 Apr; 27(4):366-72.
Score: 0.001
-
Comparison of in vivo and in vitro glucocorticoid sensitivity in depression: relationship to the dexamethasone suppression test. Biol Psychiatry. 1988 Oct; 24(6):619-30.
Score: 0.001
-
Comparison of T8+ cell-mediated suppressor and cytotoxic functions in multiple sclerosis. J Neuroimmunol. 1986 Sep; 12(3):215-24.
Score: 0.001
-
Suppressor and cytolytic cell function in multiple sclerosis. Effects of cyclosporine A and interleukin 2. J Clin Invest. 1986 Aug; 78(2):582-6.
Score: 0.001
-
An epitope shared by central nervous system myelin and peripheral blood macrophages. J Neuroimmunol. 1986 Jul; 12(1):49-55.
Score: 0.001
-
Activated suppressor cell dysfunction in progressive multiple sclerosis. J Immunol. 1986 Jul 01; 137(1):137-41.
Score: 0.001
-
Dissociation of T8+ cell-mediated cytolytic and suppressor functions in young adults. J Clin Lab Immunol. 1986 Jun; 20(2):51-5.
Score: 0.001
-
Senile dementia of Alzheimer's type (SDAT): reduced T8+-cell-mediated suppressor activity. Neurology. 1985 Nov; 35(11):1635-8.
Score: 0.001
-
Glucocorticoid receptors in depression: relationship to the dexamethasone suppression test. Am J Psychiatry. 1985 Nov; 142(11):1278-84.
Score: 0.001
-
Age-related changes in mechanisms accounting for low levels of polyclonally induced immunoglobulin secretion in humans. Clin Immunol Immunopathol. 1985 May; 35(2):191-9.
Score: 0.001
-
Hypercortisolism and depression. N Engl J Med. 1985 Mar 21; 312(12):791-2.
Score: 0.001
-
Glucocorticoid resistance in depression: the dexamethasone suppression test and lymphocyte sensitivity to dexamethasone. Am J Psychiatry. 1984 Nov; 141(11):1365-70.
Score: 0.001
-
Multiple sclerosis: relation of in vitro IgG secretion to T suppressor cell number and function. Neurology. 1984 Sep; 34(9):1155-60.
Score: 0.001
-
T cell regulation of polyclonally induced immunoglobulin secretion in humans. J Immunol. 1984 Apr; 132(4):1779-83.
Score: 0.001
-
Analysis of T regulator cell surface markers and functional properties in multiple sclerosis. J Neuroimmunol. 1984 Apr; 6(2):93-103.
Score: 0.001